OVERVIEW

BPC‑157, TB‑500, GHK‑Cu (Glow Blend) is a combination of three peptides commonly used in research for their potential regenerative, repair, and skin‑enhancing properties. BPC‑157 is a 15‑amino‑acid peptide derived from a naturally occurring gastric protein, studied in animal and laboratory models for its ability to promote tissue repair, angiogenesis (formation of new blood vessels), and modulation of inflammation. TB‑500, a synthetic fragment of thymosin beta‑4, complements this by supporting cellular migration, tissue remodeling, and connective tissue recovery. GHK‑Cu (Copper Peptide) is a tripeptide bound to copper that has been investigated for its role in stimulating collagen and elastin production, supporting skin regeneration, and providing antioxidant and anti-inflammatory effects. Together, these peptides are often combined in topical or injectable “Glow Blends” for experimental use in improving tissue healing, reducing inflammation, and promoting skin health and overall regenerative potential, based primarily on preclinical studies.

Despite growing interest, the Glow Blend is not approved by the U.S. Food and Drug Administration for therapeutic or cosmetic use. Most evidence comes from animal studies, cell models, or small-scale research, and the safety, efficacy, and optimal dosing in humans remain largely untested. Products marketed with these peptides are usually sold as “research chemicals,” and quality or purity can vary widely. Components such as BPC‑157 and TB‑500 are prohibited by the World Anti‑Doping Agency due to potential performance-enhancing effects. Therefore, self-administration carries significant safety, legal, and ethical risks, and any exploration of these peptides should be limited to controlled research settings with qualified oversight.